MedLensLoading…
Tablets USP · RxChange Co.
Dosage Form
Tablets USP
Manufacturer
RxChange Co.
This medication contains important usage instructions, warnings, and side effect information that you should review before use.
See full prescribing information for complete boxed warning.
Lisinopril tablets are contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema.
Lisinopril has been found to be generally well tolerated in controlled clinical trials involving 1969 patients with hypertension or heart failure. For the most part, adverse experiences were mild and transient.
Following a single oral dose of 20 g/kg no lethality occurred in rats, and death occurred in one of 20 mice receiving the same dose. The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution.
Lisinopril can be removed by hemodialysis (See WARNINGS, Anaphylactoid Reactions During Membrane Exposure).
Lisinopril is an oral long-acting angiotensin converting enzyme inhibitor. Lisinopril, a synthetic peptide derivative, is chemically described as (S)-1-[N2 -(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline dihydrate. Its empirical formula is C21H31N3O5(2H2O and its structural formula is:
[image: MM1]Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.53. It is soluble in water and sparingly soluble in methanol and practically insoluble in ethanol.
Lisinopril tablets USP are supplied as 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg tablets for oral administration.
Inactive Ingredients:
2.5 mg tablets - colloidal silicon dioxide, dibasic calcium phosphate, magnesium stearate, mannitol, pre-gelatinized starch, starch.
5 mg, 10 mg, 20 mg and 30 mg tablets – colloidal silicon dioxide, dibasic calcium phosphate, magnesium stearate, mannitol, pre-gelatinized starch, red iron oxide, starch.
40 mg tablets - colloidal silicon dioxide, dibasic calcium phosphate, magnesium stearate, mannitol, pre-gelatinized starch, starch, yellow iron oxide.
[image: MM4]
Lisinopril Tablets, USP are available as:
2.5 mg tablet is a white to off-white, round, biconvex, uncoated, tablet with "LUPIN" debossed on one side and "2.5" on other side. They are available as follows:
Bottles of 90 NDC 68180-512-09
Bottles of 100 NDC 68180-512-01
Bottles of 500 NDC 68180-512-02
Bottles of 1000 NDC 68180-512-03
5 mg tablet is a pink coloured, round, biconvex, uncoated, tablet with "5" debossed on one side and breakline on other side. They are available as follows:
Bottles of 90 NDC 68180-513-09
Bottles of 100 NDC 68180-513-01
Bottles of 500 NDC 68180-513-02
Bottles of 1000 NDC 68180-513-03
Bottles of 5000 NDC 68180-513-05
10 mg tablet is a pink coloured, round, biconvex, uncoated, tablet with "LUPIN" debossed on one side and "10" on other side. They are available as follows:
Bottles of 90 NDC 68180-514-09
Bottles of 100 NDC 68180-514-01
Bottles of 500 NDC 68180-514-02
Bottles of 1000 NDC 68180-514-03
Bottles of 5000 NDC 68180-514-05
20 mg tablet is a pink coloured, round, biconvex, uncoated, tablet with "LUPIN" debossed on one side and "20" on other side. They are available as follows:
Bottles of 90 NDC 68180-515-09
Bottles of 100 NDC 68180-515-01
Bottles of 500 NDC 68180-515-02
Bottles of 1000 NDC 68180-515-03
Bottles of 5000 NDC 68180-515-05
30 mg tablet is a red coloured, round, biconvex, uncoated, tablet with "LUPIN" debossed on one side and "30" on other side. They are available as follows:
Bottles of 90 NDC 68180-516-09
Bottles of 100 NDC 68180-516-01
Bottles of 500 NDC 68180-516-02
Bottles of 1000 NDC 68180-516-03
40 mg tablet is a yellow coloured, round, biconvex, uncoated, tablet with "LUPIN" debossed on one side and "40" on other side. They are available as follows:
Bottles of 90 NDC 68180-517-09
Bottles of 100 NDC 68180-517-01
Bottles of 500 NDC 68180-517-02
Bottles of 1000 NDC 68180-517-03
Bottles of 2000 NDC 68180-517-04
Storage:
Store at 20º to 25ºC (68º to 77ºF)[see USP Controlled Room Temperature]. Protect from moisture, freezing and excessive heat. Dispense in a tight container.
Photos of the product and/or packaging supplied by the manufacturer.
2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg
Rx only
Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of lisinopril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. In hypertensive patients with normal renal function treated with lisinopril alone for up to 24 weeks, the mean increase in serum potassium was approximately 0.1 mEq/L; however, approximately 15% of patients had increases greater than 0.5 mEq/L and approximately 6% had a decrease greater than 0.5 mEq/L. In the same study, patients treated with lisinopril and hydrochlorothiazide for up to 24 weeks had a mean decrease in serum potassium of 0.1 mEq/L; approximately 4% of patients had increases greater than 0.5 mEq/L and approximately 12% had a decrease greater than 0.5 mEq/L. (See PRECAUTIONS). Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity.
ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of lisinopril remains to be elucidated.
While the mechanism through which lisinopril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, lisinopril is antihypertensive even in patients with low-renin hypertension. Although lisinopril was antihypertensive in all races studied, Black hypertensive patients (usually a low-renin hypertensive population) had a smaller average response to monotherapy than non-Black patients.
Concomitant administration of lisinopril and hydrochlorothiazide further reduced blood pressure in Black and non-Black patients and any racial differences in blood pressure response were no longer evident.
Manufactured for:
Lupin Pharmaceuticals, Inc.
Baltimore, Maryland 21202
United States.
Manufactured by:
Lupin Limited
Goa 403 722
INDIA.
Or
Lupin Limited
Pithampur (M.P.) 454 775
INDIA.
Revised: July 5, 2013 ID#: 233363
Create a free account to view complete drug information, save medications, and more.
Free forever · No credit card required